TY - JOUR
T1 - Post-stroke depression
T2 - Chaos to exposition
AU - Sarkar, Ankan
AU - Sarmah, Deepaneeta
AU - Datta, Aishika
AU - Kaur, Harpreet
AU - Jagtap, Priya
AU - Raut, Swapnil
AU - Shah, Birva
AU - Singh, Upasna
AU - Baidya, Falguni
AU - Bohra, Mariya
AU - Kalia, Kiran
AU - Borah, Anupom
AU - Wang, Xin
AU - Dave, Kunjan R.
AU - Yavagal, Dileep R.
AU - Bhattacharya, Pallab
N1 - Funding Information:
Authors acknowledge Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, Govt. of India and National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, Gandhinagar, India.
PY - 2021/3
Y1 - 2021/3
N2 - Cerebral ischemia contributes to significant disabilities worldwide, impairing cognitive function and motor coordination in affected individuals. Stroke has severe neuropsychological outcomes, the major one being a stroke. Stroke survivors begin to show symptoms of depression within a few months of the incidence that overtime progresses to become a long-term ailment. As the pathophysiology for the progression of the disease is multifactorial and complex, it limits the understanding of the disease mechanism completely. Meta-analyses and randomized clinical trials have shown that intervening early with tricyclic antidepressants and selective serotonin receptor inhibitors can be effective. However, these pharmacotherapies possess several limitations that have given rise to newer approaches such as brain stimulation, psychotherapy and rehabilitation therapy, which in today's time are gaining attention for their beneficial results in post-stroke depression (PSD). The present review highlights numerous factors like lesion location, inflammatory mediators and genetic abnormalities that play a crucial role in the development of depression in stroke patients. Further, we have also discussed various mechanisms involved in post-stroke depression (PSD) and strategies for early detection and diagnosis using biomarkers that may revolutionize treatment for the affected population. Towards the end, along with the preclinical scenario, we have also discussed the various treatment approaches like pharmacotherapy, traditional medicines, psychotherapy, electrical stimulation and microRNAs being utilized for effectively managing PSD.
AB - Cerebral ischemia contributes to significant disabilities worldwide, impairing cognitive function and motor coordination in affected individuals. Stroke has severe neuropsychological outcomes, the major one being a stroke. Stroke survivors begin to show symptoms of depression within a few months of the incidence that overtime progresses to become a long-term ailment. As the pathophysiology for the progression of the disease is multifactorial and complex, it limits the understanding of the disease mechanism completely. Meta-analyses and randomized clinical trials have shown that intervening early with tricyclic antidepressants and selective serotonin receptor inhibitors can be effective. However, these pharmacotherapies possess several limitations that have given rise to newer approaches such as brain stimulation, psychotherapy and rehabilitation therapy, which in today's time are gaining attention for their beneficial results in post-stroke depression (PSD). The present review highlights numerous factors like lesion location, inflammatory mediators and genetic abnormalities that play a crucial role in the development of depression in stroke patients. Further, we have also discussed various mechanisms involved in post-stroke depression (PSD) and strategies for early detection and diagnosis using biomarkers that may revolutionize treatment for the affected population. Towards the end, along with the preclinical scenario, we have also discussed the various treatment approaches like pharmacotherapy, traditional medicines, psychotherapy, electrical stimulation and microRNAs being utilized for effectively managing PSD.
KW - Biomarkers
KW - Depression
KW - Diagnosis
KW - Post-stroke depression
KW - Repetitive transcranial magnetic stimulation
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=85098698485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098698485&partnerID=8YFLogxK
U2 - 10.1016/j.brainresbull.2020.12.012
DO - 10.1016/j.brainresbull.2020.12.012
M3 - Review article
C2 - 33359639
AN - SCOPUS:85098698485
VL - 168
SP - 74
EP - 88
JO - Brain Research Bulletin
JF - Brain Research Bulletin
SN - 0361-9230
ER -